cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit
Launched by CORPORACION PARC TAULI · Feb 17, 2025
Trial Information
Current as of June 28, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
There is very little recent data on the prevalence of advance chronic liver disease in high-risk patients, particularly in our region, making studies evaluating this necessary.
In the European clinical practice guidelines (EASL Clinical Practice Guidelines: Management of Alcohol-Related Liver Disease), it is recommended to screen for advance chronic liver disease in high-risk populations such as patients in rehabilitation and detox clinics and heavy drinkers. advance chronic liver disease should be considered in patients presenting with extrahepatic manifestations of alcohol use disorder, ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to the detoxification unit for alcohol use disorder
- • Patients admitted to the psychiatry unit for dual pathology with harmful alcohol consumption (\> 30 g/day in men (3 standard drinks) and \> 20 g/day in women (2 standard drinks))
- Exclusion Criteria:
- • Refusal to undergo additional tests (blood analysis, ultrasound, and FibroScan)
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Trial Officials
Jordi Sánchez Delgado, MD. PhD
Principal Investigator
Consorci Corporació Sanitària Parc Taulí
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported